Ran Ben-Tzur

3 weeks ago | jdsupra.com | David Bell |Ran Ben-Tzur |Wendy Grasso

Acting SEC Chair Mark T. Uyeda outlined potential regulatory changes to make IPOs more attractive and to scale public company disclosures at the Florida Bar’s 41st Annual Federal Securities Institute and M&A Conference.

3 weeks ago | jdsupra.com | David Bell |Ran Ben-Tzur |Wendy Grasso

Some proxy advisors and institutional investors have made changes to their diversity policies and mandates, including the following: ISS will no longer consider gender, racial, or ethnic diversity for director election recommendations for reports published on or after February 25.

3 weeks ago | jdsupra.com | David Bell |Ran Ben-Tzur |Wendy Grasso

The SEC published updated Compliance and Disclosure Interpretations on the filing of Schedules 13D and 13G/Shareholder Engagement. Revised Question 103.11 – This CDI was revised to state that a shareholder’s ability to file on Schedule 13G in lieu of the Schedule 13D otherwise required will be informed by the meaning of “control” as defined in Exchange Act Rule 12b-2.

1 month ago | jdsupra.com | David Bell |Ran Ben-Tzur |Wendy Grasso

The SEC rescinded Staff Legal Bulletin No. 14L and issued updated guidance on the exclusion of shareholder proposals under Rule 14a-8 and certain other aspects of Rule 14a-8.  Economic Relevance Exclusion: The SEC staff will now focus on a proposal’s significance to a company’s specific business when it relates to operations accounting for less than 5% of total assets, net earnings, and gross sales, rather than the abstract social or ethical significance of an issue.

1 month ago | jdsupra.com | David Bell |Ran Ben-Tzur |Wendy Grasso

The Securities and Exchange Commission has expanded the confidential filing options, including:  All Securities Act registration statements may now be submitted confidentially, regardless of how much time has passed since a company’s IPO. A confidential submission for a follow-on offering must be made publicly available on EDGAR at least two business days prior to effectiveness.